Page last updated: 2024-10-30

mebendazole and Parkinson Disease

mebendazole has been researched along with Parkinson Disease in 1 studies

Mebendazole: A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.
mebendazole : A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5.

Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gatto, M1
Fernandez Pardal, M1
Melero, M1
Zurru, C1
Scorticati, C1
Micheli, F1

Other Studies

1 other study available for mebendazole and Parkinson Disease

ArticleYear
L-dopa malabsorption in a parkinsonian patient with Strongyloides stercoralis duodenitis.
    Clinical neuropharmacology, 1994, Volume: 17, Issue:1

    Topics: Aged; Animals; Duodenitis; Humans; Intestinal Diseases, Parasitic; Levodopa; Male; Mebendazole; Metr

1994